DermTech Settles Medicare False Claims Allegations Over Unreliable Skin Cancer Tests
DermTech, the skin cancer testing company which filed for bankruptcy in 2024 and is now liquidating as DTech Liquidating, has agreed to resolve allegations that it violated the False Claims Act by knowingly submitting claims to Medicare for unreliable tests. Under the settlement announced Wednesday, the federal government received an allowed Class Three General Unsecured Claim of $5,038,011 in DermTech’s bankruptcy proceeding.
